Total Neoadjuvant Therapy vs. Standard Treatment for Rectal Cancer
Author Information
Author(s): Foroughi Freshte, Javadinia Seyed Alireza, Salek Roham
Primary Institution: Mashhad University of Medical Sciences
Hypothesis
Can administering neoadjuvant chemotherapy before and after preoperative chemoradiotherapy increase the pathological complete response rates in locally advanced rectal cancer?
Conclusion
Total neoadjuvant therapy is a safe and feasible treatment approach that may improve the overall pathological complete response rate compared to standard treatment.
Supporting Evidence
- 48% of patients in the TNT group achieved a pathological complete response compared to 25.9% in the standard group.
- The R0 resection rates were similar between the two groups.
- Both treatment approaches were well-tolerated with similar toxicity rates.
Takeaway
This study looked at two ways to treat rectal cancer and found that giving more chemotherapy before surgery might help patients respond better to treatment.
Methodology
A phase 3, multicenter, randomized trial comparing total neoadjuvant therapy with standard treatment in patients with locally advanced rectal cancer.
Potential Biases
Potential bias due to non-masking of treatment allocation and changes in trial design.
Limitations
The trial design was modified during the study, which may have introduced bias.
Participant Demographics
Adult patients with biopsy-proven, locally advanced non-metastatic rectal adenocarcinoma.
Statistical Information
P-Value
0.4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website